Multiplex IHC and novel monoclonal antibodies as enabling tools for the study of tumor immunology

DATE: January 15, 2016
TIME: 7am EST, 12pm UK, 1pm CET

With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes.  IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information.  Immuno-assays with high specificity and sensitivity are a powerful tool, however, there are challenges associated with antibody based multiplexing, particularly when the analysis involves greater than 2-3 markers.  Multiplex IHC is a method that bypasses antibody species/isotype concerns, while providing signal amplification, and was thus used to examine the co-expression of immune checkpoint control proteins, such as PD-L1, B7-H4, and VISTA, in breast and ovarian cancer tissue samples. 
 
Target Audience
This webinar will be ideal for academic and pharmaceutical researchers who are interested in exploiting fluorescence immunohistochemistry as a multiplex assay to investigate the interplay and spatial orientation of multiple proteins of interest in the context of three-dimensional tissue architecture.